莱斯康制药 2025年度报告

Indicate by check mark if the registrant is not required to file reports pursuant to Section13 or Section15(d) of the Securities Exchange Act of 1934.Yes☐No☑ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filingrequirements for the past 90 days.Yes☑No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).Yes☑No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or anemerging growth company.See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” inRule 12b-2 of the Securities Exchange Act of 1934.(check one):Large accelerated filer☐Accelerated filer☐Non-accelerated filer☑Smaller reporting If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any newor revised financial accounting standards provided pursuant to Section 13(a) of the Securities Exchange Act of 1934.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internalcontrol over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared orissued its audit report.☐ If securities are registered pursuant to Section 12(b) of the Securities Exchange Act of 1934, indicate by check mark whether the financial statements ofthe registrant included in the filing reflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation receivedby any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934).Yes☐No☑ The aggregate market value of voting stock held by non-affiliates of the registrant as of the last day of the registrant’s most recently completed secondquarter was approximately $170.0 million, based on the closing price of the common stock on the Nasdaq Global Select Market on June30, 2025 of $0.95 pershare.For purposes of the preceding sentence only, our directors, executive officers and controlling stockholders are assumed to be affiliates.As of March4, Documents Incorporated by Reference Certain sections of the registrant’s definitive proxy statement relating to the registrant’s 2026 annual meeting of stockholders, which proxy statement will befiled under the Securities Exchange Act of 1934 within 120 days of the end of the registrant’s fiscal year ended December31, 2025, are incorporated byreference into Part III of this annual report on Form 10-K. Item 1.Business 1A.Risk Factors 1B.Unresolved Staff Comments 1C.Cybersecurity 2.Properties 3.Legal Proceedings 4.Mine Safety Disclosures 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations7A.Quantitative and Qualitative Disclosures About Market Risk 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 9A.Controls and Procedures 9B.Other Information 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections The Lexicon name and logo, INPEFAand ZYNQUISTA are registered trademarks of Lexicon Pharmaceuticals, Inc._____________________________________________________®® In this annual report on Form 10-K, “Lexicon Pharmaceuticals,” “Lexicon,” “the Company,” “we,” “us” and “our” refer to LexiconPharmaceuticals, Inc. and its subsidiaries. Factors Affecting Forward-Looking Statements This annual report on Form 10-K contains forward-looking statements.These statements relate to future events or our future financialperformance.We have attempted to identify forward-looking statements by terminology including “anticipate,” “believe,” “can,” “continue,”“could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “should” or “will” or the negative of these terms or othercomparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, Although we believe that the expectations reflected in